Therapeutic options in ophthalmic market expand

Article

Keeping up with developments in ophthalmic therapy could be a full-time job in itself, as new products are constantly tested and introduced, reformulated, given expanded indications, or withdrawn from the market.

Atlanta-Keeping up with developments in ophthalmic therapy could be a full-time job in itself, as new products are constantly tested and introduced, reformulated, given expanded indications, or withdrawn from the market. Tammy P. Than, MS, OD, FAAO, has saved doctors time by giving them an update on a number of these changes during her presentation at the annual SECO meeting.

Anti-infective update

Several drugs for the treatment of adenoviral conjunctivitis are in clinical trials, some with different mechanisms of action than customarily used. These include a combination of 0.1% dexamethasone and 0.4% povidone-iodine (FST-100, Foresight Biotherapeutics); an aganocide compound based on the chemical structures of naturally occurring antimicrobial agents (AL-46383A [N-chlorotaurine] NovaBay Pharmaceuticals); and a metallo-organic compound (Doxovir, OPKO Health), which has both antiviral and anti-inflammatory properties.

Bacterial conjunctivitis therapies

Among currently marketed therapies for bacterial conjunctivitis, a new formulation of the topical fluoroquinolone moxifloxacin 0.5% (Moxeza, Alcon) was approved by the FDA last fall. This agent has the same concentration as the original drug (Vigamox), but is contained in a different vehicle, xanthan gum. When this drop hits the eye, it thickens and stays on the eye longer. It is labeled for B.I.D. rather than T.I.D. use. In addition, unlike other fluoroquinolones, topical fluoroquinolone moxifloxacin 0.5% is approved for use in infants ≥ 4 months old.

A higher concentration of gatifloxacin ophthalmic solution 0.5% (Zymaxid, Allergan) was also approved last year. Because it is a stronger solution, patients may need to use it less frequently. It is labeled for B.I.D. to Q.I.D. use on days 2 to 7 of treatment.

Dr. Than also provided an update on the work of the Ocular Tracking Resistance in U.S. Today (Ocular TRUST), a longitudinal nationwide antimicrobial susceptibility surveillance program specific to ocular isolates. Reports from this group provide further evidence of increasing resistance to ophthalmic antibiotics, including widely used fluoroquinolones.

The program's tests so far have shown that methicillin-resistant Staphylococcus aureus is susceptible only to trimethoprim (available in an ophthalmic formulation as the combination agent polymyxin B sulfate and trimethoprim sulfate, [Polytrim, Allergan]) and to a lesser extent, tobramycin.

The Ocular Trust also found that all antimicrobials are less active against methicillin-resistant coagulase-negative staphylococci (CNS) than methicillin-susceptible CNS, and that macrolides, such as azithromycin, are associated with lower in vitro susceptibility rates compared with the fluoroquinolones.

One of the most frequent reasons for visits to the optometrist is for the management of ocular surface disease. Sodium fluorescein (1% ) and lissamine green (0.5%) (Fluramene, Noble Vision Group) was introduced in 2010 as a diagnostic tool for simultaneous evaluation of the cornea and conjunctiva. This one-step process may be more convenient for patients and clinicians, Dr. Than said. The product is available only from EyeSupply USA.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD; and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
© 2025 MJH Life Sciences

All rights reserved.